β-Cyclodextrin-based nanoassemblies for the treatment of atherosclerosis
Open Access
- 2 January 2024
- journal article
- review article
- Published by Oxford University Press (OUP) in Regenerative Biomaterials
- Vol. 11, rbae071
Abstract
Atherosclerosis, a chronic and progressive condition characterized by the accumulation of inflammatory cells and lipids within artery walls, remains a leading cause of cardiovascular diseases globally. Despite considerable advancements in drug therapeutic strategies aimed at managing atherosclerosis, more effective treatment options for atherosclerosis are still warranted. In this pursuit, the emergence of β-cyclodextrin (β-CD) as a promising therapeutic agent offers a novel therapeutic approach to drug delivery targeting atherosclerosis. The hydrophobic cavity of β-CD facilitates its role as a carrier, enabling the encapsulation and delivery of various therapeutic compounds to affected sites within the vasculature. Notably, β-CD-based nanoassemblies possess the ability to reduce cholesterol levels, mitigate inflammation, solubilize hydrophobic drugs and deliver drugs to affected tissues, making these nanocomponents promising candidates for atherosclerosis management. This review focuses on three major classes of β-CD-based nanoassemblies, including β-CD derivatives-based, β-CD/polymer conjugates-based and polymer β-CD-based nanoassemblies, highlighting a variety of formulations and assembly methods to improve drug delivery and therapeutic efficacy. These β-CD-based nanoassemblies exhibit a variety of therapeutic mechanisms for atherosclerosis and offer systematic strategies for overcoming barriers to drug delivery. Finally, we discuss the present obstacles and potential opportunities in the development and application of β-CD-based nanoassemblies as novel therapeutics for managing atherosclerosis and addressing cardiovascular diseases.Keywords
Funding Information
- National Natural Science Foundation of China (NSFC 32301117)
- Xiamen Natural Science Foundation Youth Project (3502Z202372035)
- Scientific Research Funds of Huaqiao University (22BS125)
This publication has 147 references indexed in Scilit:
- Autonomous in Vitro Anticancer Drug Release from Mesoporous Silica Nanoparticles by pH-Sensitive NanovalvesJournal of the American Chemical Society, 2010
- Facile Synthesis of β-Cyclodextrin-Dextran Polymers by “Click” ChemistryBiomacromolecules, 2010
- The Solubility–Permeability Interplay in Using Cyclodextrins as Pharmaceutical Solubilizers: Mechanistic Modeling and Application to ProgesteroneJournal of Pharmaceutical Sciences, 2010
- NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystalsNature, 2010
- Endocytosis of beta-cyclodextrins is responsible for cholesterol reduction in Niemann-Pick type C mutant cellsProceedings of the National Academy of Sciences, 2010
- Role of cholesterol and lipid organization in diseaseNature, 2005
- 2-Hydroxypropyl-β-cyclodextrin (HP-β-CD): A toxicology reviewFood and Chemical Toxicology, 2005
- Cyclodextrin-based pharmaceutics: past, present and futureNature Reviews Drug Discovery, 2004
- Comparison of the capacity of β-cyclodextrin derivatives and cyclophanes to shuttle cholesterol between cells and serum lipoproteinsJournal of Lipid Research, 1999
- Crystallization of Free Cholesterol in Model Macrophage Foam CellsArteriosclerosis, Thrombosis, and Vascular Biology, 1999